SOUTH SAN FRANCISCO, Calif., Nov. 9 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) today announced that on November 5, 2009, it received a letter from The NASDAQ Stock Market LLC ("Nasdaq") stating that the Nasdaq Hearing Panel has granted Anesiva's request for continued listing on The NASDAQ Global Market subject to the condition that Anesiva shall have completed on or before December 31, 2009, the proposed merger (the "Merger") contemplated by the Agreement and Plan of Merger, dated August 4, 2009, among Anesiva, Arca Acquisition Corporation ("Arca"), a wholly-owned subsidiary of Anesiva, Arcion Therapeutics, Inc. ("Arcion") and, with respect to Articles V and IX only of the agreement, each of the Arcion stockholders listed on Schedule I thereto.
On October 30, 2009, Anesiva announced that the Anesiva 2009 Annual Meeting of Stockholders will be held on December 3, 2009 at 9:00 a.m. PST at 400 Oyster Point, Suite 107A, South San Francisco, California. Stockholders of record at the close of business on October 9, 2009 will be eligible to vote at the 2009 Annual Meeting of Stockholders, at which the proposed Merger will be considered and voted upon. The definitive proxy statement for the 2009 Annual Meeting of Stockholders was mailed to stockholders on or about November 6, 2009.
Anesiva seeks to be a leader in the development and commercialization of novel pharmaceutical products for pain management. Anesiva's lead product candidate is Adlea, a novel small molecule formulation of capsaicin that is currently in development for management of both acute and chronic pain. Adlea has been shown in clinical trials to provide extended pain relief after only a single administration in a variety of localized moderate-to-severe pain conditions.
Additional Information and Where to Find
|SOURCE Anesiva, Inc.|
Copyright©2009 PR Newswire.
All rights reserved